Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 21, 2013New England Journal of MedicineOpen Access

Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease

View Full Paper
Ask AI
Bookmark
Share

Authors

William J. SandbornWilliam J. SandbornSemmelweis UniversityBrian G. FeaganBrian G. FeaganSemmelweis UniversityPaul RutgeertsPaul RutgeertsUniversity of Leeds

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Sandborn et al. (2013) studied this question.

synapsesocial.com/papers/69db2bcd5b363cdf1c835875https://doi.org/10.1056/nejmoa1215739
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Effects of Vedolizumab Induction Therapy for Patients With Crohn’s Disease in Whom Tumor Necrosis Factor Antagonist Treatment Failed2014 · 718 citations
  2. 2Treatment of Ulcerative Colitis with a Humanized Antibody to the α <sub>4</sub> β <sub>7</sub> Integrin2005 · 693 citations
  3. 3Vedolizumab for the Treatment of Active Ulcerative Colitis: A Randomized Controlled Phase 2 Dose-ranging Study2011 · 212 citations
  4. 4Maintenance treatment of Crohn's disease2003 · 33 citations
  5. 5Prevalence of Polyomavirus BK and JC Infection and Replication in 400 Healthy Blood Donors2009 · 794 citations